Johnson & Johnson (JNJ) (NYSE:JNJ) released its forecast 2019 sales earlier today. The pharmaceutical giant fell short of analyst estimates after previously reporting better-than-expected Q4 results. On the news, JNJ stock is down -2.06%, selling for $128 USD per share.

JNJ Stock

As stated, the company fell short of analyst estimations. JNJ reported 2019 forecasted sales between $80.4 billion to $81.2 billion. Analysts had predicted an average figure of $82.69 billion, according to IBES data from Refinitiv.

JNJ stock is suffering as a result. 

Q4 Results

Despite the negative results, JNJ reported Q4 results that exceeded Wall Street estimates. Q4 sales rose to $20.39 billion from $20.20 billion. Wall Street set its estimate at $20.20 billion.

The rise was led by JNJ’s Crohn’s disease treatment Stelara. Pharmaceutical sales rose 5.3% to $10.19 billion in the fourth quarter. Analysts had expected revenue of $10.08 billion for the sector.

Overall, the company posted a net profit of $3.04 billion, which equaled $1.12 per JNJ stock. Johnson & Johnson showed investors an impressive year that trumped the previous year. In 2018, it made a loss of $10.71 billion, or $3.99 per share, much of this attested to a $13.6 billion charge for changes in US tax law.

>> Oxfam Report: World’s Richest Own as Much as 50% Poorest